Group items tagged

The National Institute for Health and Care Excellence (NICE) has rejected the use of olaparib on the NHS for treatment of adults with hormone-relapsed prostate cancer with BRCA1 or BRCA2 mutations which has spread to other parts of the body. In a draft guidance issued today (January 5) NICE said evidence around the drug made by AstraZeneca was uncertain and approving it would not be a good use of NHS funds. Current treatment for metastatic prostate cancer that no longer responds to hormone therapy is chemotherapy with docetaxel, cabazitaxel, or radium 223 dichloride - a treatment option for people with symptomatic bone metastases who have already had docetaxel or cannot have it. NICE said: "Clinical trial evidence showed that people taking olaparib have more time before their disease gets worse, and live longer overall, than people having retreatment with abiraterone or enzalutamide. However, retreatment with abiraterone or enzalutamide is not considered effective and is not standard care in the NHS.

Otrivine brings the world's first air-purifying "Air Bubble" to Glasgow in a bid to raise awareness of the devastating effect of air pollution on children's health. Air pollution is considered the world's largest environmental health threat, with 93 per cent of children breathing polluted air every day according to the World Health Organisation (WHO). The Air Bubble, launched to help bring this invisible crisis to the top of the agenda, is an educational architecture, using biotechnology to purify the air. The nose is one of our first lines of defence when it comes to filtering out particle pollutants from the air we breathe. As a world leader in nasal health, Otrivine is demonstrating how innovative nature-based technology can expand the functionality of our nose to 'clean' the air we breathe in polluted urban environments.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised healthcare professionals to ensure appropriate patient counselling takes place and patients are aware of the missing information on the patient information leaflet (PIL) of Decongestant Tablets and Decongestant with Pain Relief Tablets. The advise came after Boots has identified an error with the printed PIL provided with batches of the tablets. Check the website for more information.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

England is set to reopen temporary field hospitals to contain a possible overspill of inpatients due to a surge in coronavirus cases, the national health service said Thursday. Fuelled by the highly contagious Omicron variant, daily cases have ballooned, standing at more than 183,000 on Wednesday. NHS England said it would start building the structures in the grounds of eight hospitals in cities including London, Bristol and Leeds from this week, with each designed to house around 100 extra patients. "Given the high level of Covid-19 infections and increasing hospital admissions, the NHS is now on a war footing," National medical director Stephen Powis said. The extra beds are designed for patients who are recovering from illnesses, including those who no longer have Covid, to free up space and staff to treat large numbers of virus cases.

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5). Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second half of 2023, the company said.

The NHS's latest report on ambulance services in England for March 2024 reveals significant progress in response times for emergency calls across all categories compared to recent months. The Ambulance Quality Indicators (AQI) Statistical Note, released in April, underscores both improvements and persistent challenges within the sector. Recent figures obtained from the Liberal Democratic party suggest ongoing struggles with response times, particularly for category two patients, which may include individuals experiencing strokes or heart attacks requiring a response within 18 minutes. Similarly, in November last year, ambulance waits for category 2 calls surged to their highest level since December 2022, reaching 93 minutes, after dropping to 32 minutes in January 2023 according to the British Heart Foundation. However, according to the latest statistical figures obtained from AQI, March 2024 witnessed the shortest average response times for all four categories of emergency calls since August 2023.

NHS England is set to roll out a new test this week that will help doctors to spot a rare form of eye cancer in babies in the womb. The NHS test developed at Birmingham Women's and Children's NHS Foundation Trust, identifies the risk of developing retinoblastoma in babies that can be monitored and treated sooner - increasing the chance of saving their eyesight and potentially their lives. The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk. "The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100 per cent accuracy if the baby will develop retinoblastoma," the NHS said.

ITV on Tuesday (Aug 15) said it had agreed to invest in pain relief brand Flarin Holdings Ltd, making it the British broadcaster's first consumer healthcare investment. The company has agreed to subscribe for £2 million worth of shares in Flarin, with an option to subscribe for two more tranches of 1.5 million pounds each. In return, Flarin would get advertising space across ITV's channels and ITVX. ITV said its investment will "help Flarin build mass market brand awareness by bringing the brand to millions of consumers via ITV platforms. This will be a step change in the size of the campaign and the approach to scaling the Flarin brand to date." Director of ITV AdVentures, Sheena Amin, said: "It's fantastic to be announcing our latest Media for Equity investment into Flarin. With its innovative and patented lipid technology, Flarin offers many unique benefits to those suffering from joint and muscular pain compared to any other product on the market. Flarin is already one of the fastest growing analgesics in the market and I am confident that we will see the company grow to new heights following a brand building campaign across ITV."

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

NHS England delivered 358 million general practice (GP) appointments, including Covid-19 vaccinations, in the 12 months to October 2023, an increase of 50.9 million compared to October 2019. This equals to 44 more appointments per practice per working day, with over 70 per cent of these taking place within two weeks of booking, data published by NHSE on Thursday (30 November) showed. Health Minister, Andrea Leadsom, thanked GPs and primary care teams across the country for making it possible to deliver around 32,500 more appointments every day, which clearly demonstrate that "more people are getting the care they need, when they need it." "While this is positive news, we know that there is more to do to make it easier and quicker for patients to contact their general practice and continue to focus on delivering the Primary Care Recovery Plan," she added. The Primary Care Recovery Plan published earlier this year is focused on improving access to primary care. It provided GPs in England with £240 million to support them to embrace the latest technology to tackle the 8am rush, and handle more appointments. As of August 2023, more than 1,000 general practices had signed up to digital upgrades to make booking GP appointments easier.

The World Health Organization says it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous. It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3. The WHO said on Monday (April 11) it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential". Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause. For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.

Indian pharmaceutical companies are gearing up to become global suppliers of repurposed Covid-19 drugs. With the launch of new innovative Covid-19 oral drugs, Indian companies are again expected to grab opportunities in the global supply of oral Covid-19 drugs, according to data and analytics company GlobalData. As several countries witness increasing cases of Covid-19 despite vaccination, they have started booking supply orders for innovative Covid-19 treatments like antibody cocktails, monoclonal antibodies and the latest addition such Merck's the oral Covid-19 drug 'molnupiravir'. Prashant Khadayate, pharma analyst at GlobalData, comments: "Oral treatment for Covid-19 would be the most convenient option for the patients ranging from mild to moderate Covid-19 and would not require a hospital setting. Currently, a majority of the Covid-19 treatments require a hospital setting." According to GlobalData's Pharma Intelligence Center, the UK is the first country to approve molnupiravir which is in pre-registration stage in the US, EU and Japan.

Thousands of people in Britain infected with HIV and hepatitis C through contaminated blood transfusions will receive a compensation payment decades after the scandal, the government announced on Wednesday (August 17). The payment of £100,000 ($121,000) to each victim is an interim one after Brian Langstaff, the chairman of a public inquiry into the long-running scandal, last month recommended making immediate payouts before waiting for an ongoing inquiry to conclude. The former High Court judge said that the "moral case for compensation is beyond doubt". The government said the tax-free payments, to survivors of the scandal and bereaved partners of the thousands estimated to have died from the contaminated blood, would be made by the end of October. Thousands of people with haemophilia contracted hepatitis C and HIV after receiving blood transfusions, mainly from the United States, through the NHS in the 1970s, 1980s and 1990s. Due to a shortage of blood products in Britain, the NHS bought much of its stock from US suppliers whose donors, including prisoners and other groups at high risk of infection, had been paid for their blood.

The drug, alpelisib, which is the 100th cancer drug that has being fast-tracked to patients under the NHS Cancer Drugs Fund (CDF) will be used in combination with the hormone therapy, fulvestrant, to target the gene that causes fast-growing tumours. Up to 3,000 people a year with a certain type of secondary breast cancer will benefit from the treatment. The approach has contributed to people in England having access to nearly one third more cancer drugs compared to the European average. The drug which is manufactured by pharmaceutical company Novartis, is part of a growing number of precision treatments that target a tumour based on mutations in its DNA and that the NHS is rolling out. John Stewart, NHS National Director for Specialised Commissioning said, "In just over five years, more than 80,000 people have benefitted from earlier access to a range of cancer drugs, with people in England having access to nearly one third more cancer drugs compared to the European average, and this latest innovative new treatment will help up to 3,000 more to live a better quality of life.

GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot. The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators. The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said. "To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022." No safety concerns were identified. This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.